Clinical trial
The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral…
NCT00289003 · Biotec Pharmacon ASA, Industry · Completed
Key facts
| NCT number | NCT00289003 |
|---|---|
| Title | The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients |
| Official title | An Exploratory, Randomised, Parallel Group Study, Comparing the Protective Effect of Soluble Beta-1,3/1,6-Glucan or Placebo in Oral Mucositis in Head and Neck Cancer Patients Receiving Radiation Therapy or Chemoradiotherapy |
| Lead sponsor | Biotec Pharmacon ASA, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Oral Mucositis |
| Intervention type | Drug |
| Interventions | Soluble beta-1, 3/1, 6-glucan |
| Enrollment | 40 |
| Start date | Oct 1, 2003 |
| Completion | Jul 1, 2006 |
| First posted | Feb 9, 2006 |
| Last update posted | Jan 17, 2007 |
| Countries | Germany, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: